Early treated Perinatally HIV Infected individuals: Improving Children’s Actual Life
The EPIICAL Consortium, funded by an unrestricted industry grant, aims to implement a predictive platform for the early identification of novel therapeutic strategies for HIV infected children.
This involves developing and applying statistical and mathematical modelling to data derived from cohorts of early treated infants and children to identify virological, immunological and transcriptomic profiles associated with early control of HIV infection after ART initiation as well as viral control following ART interruption. As coordinator, Penta provides general project leadership and coordination at scientific and technical levels, as well as co-leading the design and implementation of proof of concept study protocols.
Penta and the EPIICAL project have received a financial contribution from ViiV Healthcare U.K. (ViiV). ViiV does not have any operational or executive control over the project. Additionally, ViiV does not have or exercise any editorial control over the publication or generation of results from the EPIICAL project (if any). Sole responsibility for the EPIICAL project, including handling, management, publications and/or reported outcomes, lies with Penta and its affiliates.